Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.

Jeremić, Branislav; Casas, Francesc; Dubinsky, Pavol; Gomez-Caamano, Antonio; Cihoric, Nikola; Videtic, Gregory; Igrutinovic, Ivan (2018). Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer. Frontiers in oncology, 8(30), p. 30. Frontiers Research Foundation 10.3389/fonc.2018.00030

[img]
Preview
Text
fonc-08-00030.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (138kB) | Preview

While there are no established pretreatment predictive and prognostic factors in patients with stage IIIA/pN2 non-small cell lung cancer (NSCLC) indicating a benefit to surgery as a part of trimodality approach, little is known about treatment-related predictive and prognostic factors in this setting. A literature search was conducted to identify possible treatment-related predictive and prognostic factors for patients for whom trimodality approach was reported on. Overall survival was the primary endpoint of this study. Of 30 identified studies, there were two phase II studies, 5 "prospective" studies, and 23 retrospective studies. No study was found which specifically looked at treatment-related predictive factors of improved outcomes in trimodality treatment. Of potential treatment-related prognostic factors, the least frequently analyzed factors among 30 available studies were overall pathologic stage after preoperative treatment and UICC downstaging. Evaluation of treatment response before surgery and by pathologic tumor stage after induction therapy were analyzed in slightly more than 40% of studies and found not to influence survival. More frequently studied factors-resection status, degree of tumor regression, and pathologic nodal stage after induction therapy as well as the most frequently studied factor, the treatment (in almost 75% studies)-showed no discernible impact on survival, due to conflicting results. Currently, it is impossible to identify any treatment-related predictive or prognostic factors for selecting surgery in the treatment of patients with stage IIIA/pN2 NSCLC.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Cihoric, Nikola

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2234-943X

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

21 Jun 2018 10:43

Last Modified:

23 Oct 2019 18:12

Publisher DOI:

10.3389/fonc.2018.00030

PubMed ID:

29527511

Uncontrolled Keywords:

non-small cell lung cancer predictive factors prognostic factors stage IIIA/pN2 trimodality therapy

BORIS DOI:

10.7892/boris.113402

URI:

https://boris.unibe.ch/id/eprint/113402

Actions (login required)

Edit item Edit item
Provide Feedback